Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer

Yingqiu Xie, Wenfu Lu, Shenji Liu, Qing Yang, Brett S. Carver, Estelle Li, Yuzhuo Wang, Ladan Fazli, Martin Gleave, Zhenbang Chen

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


Castration-resistant prostate cancer (PCa) (CRPC) is relapse after various forms of androgen ablation therapy and causes a major mortality in PCa patients, yet the mechanism remains poorly understood. Here, we report the nuclear form of mesenchymal epithelial transition factor (nMET) is essential for CRPC. Specifically, nMET is remarkably increased in human CRPC samples compared with naïve samples. Androgen deprivation induces endogenous nMET and promotes cell proliferation and stem-like cell self-renewal in androgen-nonresponsive PCa cells. Mechanistically, nMET activates SRY (sex determining region Y)-box9, β-catenin, and Nanog homeobox and promotes sphere formation in the absence of androgen stimulus. Combined treatment of MET and β-catenin enhances the inhibition of PCa cell growth. Importantly, MET accumulation is detected in nucleus of recurrent prostate tumors of castrated Pten/Trp53 null mice, whereas MET elevation is predominantly found in membrane of naïve tumors. Our findings reveal for the first time an essential role of nMET association with SOX9/β-catenin in CRPC in vitro and in vivo, highlighting that nuclear RTK activate cell reprogramming to drive recurrence, and targeting nMET would be a new avenue to treat recurrent cancers.

Original languageEnglish
Pages (from-to)1629-1639
Number of pages11
JournalMolecular Endocrinology
Issue number10
Publication statusPublished - Oct 1 2014

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology


Dive into the research topics of 'Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this